Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
- C. Hiemke, N. Bergemann, P. Baumann
- Medicine, PsychologyPharmacopsychiatry
- 14 September 2017
Following the new guidelines for therapeutic drug monitoring in psychiatry holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.
Interindividual Variability of the Clinical Pharmacokinetics of Methadone
- C. Eap, T. Buclin, P. Baumann
- MedicineClinical Pharmacokinetics
- 2002
Because of the high morbidity and mortality associated with opioid dependence, it is of major importance that methadone is used at an effective dosage in maintenance treatment: at least 60 mg/day, but typically 80–100 mg/ day.
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.
- C. Hiemke, P. Baumann, G. Zernig
- Medicine, PsychologyPharmacopsychiatry
- 6 July 2014
Following guidelines for TDM in psychiatry will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems, and one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data.
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
- S. Crettol, J. Déglon, C. Eap
- BiologyClinical pharmacology and therapy
- 1 December 2005
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
- P. Baumann, C. Hiemke, G. Zernig
- Psychology, MedicinePharmacopsychiatry
- 1 November 2004
Therapeutic Drug Monitoring (TDM) is a valid tool to optimise pharmacotherapy. It enables the clinician to adjust the dosage of drugs according to the characteristics of the individual patient. In…
Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity
A low oral dose of midazolam can be used to measure the in vivo CYP3A activity, either by the determination of total 1′OH-midZolam/midazol am ratios at 30 min or by thedetermination of midAZolam plasma levels between 1.5 h and 4 h after its administration.
ABCB1 and Cytochrome P450 Polymorphisms: Clinical Pharmacogenetics of Clozapine
- E. Jaquenoud Sirot, B. Knežević, C. Eap
- Medicine, BiologyJournal of Clinical Psychopharmacology
- 1 August 2009
This study has shown for the first time a significant in vivo role of CYP2C19 and the P-gp transporter in the pharmacokinetics of clozapine.
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
- L. Fjordside, U. Jeppesen, C. Eap, K. Powell, P. Baumann, K. Brøsen
- Chemistry, MedicinePharmacogenetics (London)
- 1 February 1999
This study shows that CYP2D6 catalyses the metabolism of R- and S-fluoxetine and most likely the further metabolism of S-norflu oxetine but not of R -norfluxetine.
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.
- C. Hiemke, P. Baumann, G. Zernig
- Medicine, PsychologyPharmacopsychiatry
- 1 September 2011
Following guidelines for TDM in psychiatry will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems, and one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data.
Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors
- P. Baumann
- Medicine, BiologyClinical Pharmacokinetics
- 1 December 1996
No clearcut plasma concentration-clinical effectiveness relationship in patients with depression has been shown, nor any threshold which defines toxic concentrations, and SSRIs presently available may be explained by their low toxicity and use at dosages where serious adverse effects do not appear.
...
...